CAT

904.44

-3.82%↓

328.16

-0.05%↓

GEV.US

934.37

-3.04%↓

RTX

180.96

+0.81%↑

215.56

-0.77%↓

CAT

904.44

-3.82%↓

328.16

-0.05%↓

GEV.US

934.37

-3.04%↓

RTX

180.96

+0.81%↑

215.56

-0.77%↓

CAT

904.44

-3.82%↓

328.16

-0.05%↓

GEV.US

934.37

-3.04%↓

RTX

180.96

+0.81%↑

215.56

-0.77%↓

CAT

904.44

-3.82%↓

328.16

-0.05%↓

GEV.US

934.37

-3.04%↓

RTX

180.96

+0.81%↑

215.56

-0.77%↓

CAT

904.44

-3.82%↓

328.16

-0.05%↓

GEV.US

934.37

-3.04%↓

RTX

180.96

+0.81%↑

215.56

-0.77%↓

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.28 -5.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.29

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+734.31% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-162M 464M
Предишно отваряне	7.16
Предишно затваряне	1.28

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.06.2026 г., 19:20 ч. UTC

Значими двигатели на пазара

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5.06.2026 г., 21:27 ч. UTC

Печалби

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5.06.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Hog Futures Tumble to Close Week -- Market Talk

5.06.2026 г., 19:10 ч. UTC

Пазарно говорене

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5.06.2026 г., 19:03 ч. UTC

Пазарно говорене

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5.06.2026 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5.06.2026 г., 18:47 ч. UTC

Пазарно говорене

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5.06.2026 г., 18:34 ч. UTC

Пазарно говорене

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5.06.2026 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5.06.2026 г., 17:50 ч. UTC

Печалби

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5.06.2026 г., 17:27 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5.06.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 15:26 ч. UTC

Пазарно говорене

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5.06.2026 г., 15:25 ч. UTC

Печалби

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5.06.2026 г., 15:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.06.2026 г., 15:16 ч. UTC

Пазарно говорене

Zcash Tumbles After Exploit Found -- Market Talk

5.06.2026 г., 15:09 ч. UTC

Пазарно говорене

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5.06.2026 г., 15:07 ч. UTC

Пазарно говорене

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5.06.2026 г., 15:05 ч. UTC

Пазарно говорене

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

734.31% нагоре

12-месечна прогноза

Среден 11.43 USD 734.31%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.